In a report released today, Gil Blum from Needham maintained a Buy rating on Crispr Therapeutics AG, with a price target of $81.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Gil Blum’s rating is based on a combination of factors including Crispr Therapeutics AG’s recent financial performance and strategic developments. The company reported significant growth in Casgevy sales through its collaboration with Vertex, showing a 140% increase quarter-over-quarter. Despite Crispr’s revenue recognition lagging, the substantial cash reserves of $1.7 billion provide a strong financial foundation.
Additionally, upcoming updates in Crispr’s pipeline, particularly for CTX112 in NHL and AID, are expected in the latter half of 2025. These developments, although slightly delayed, are not anticipated to adversely affect the overall timeline. The focus on in vivo gene editors, which aim to offer one-time treatments for severe conditions, further strengthens the company’s potential for future growth and innovation.
According to TipRanks, Blum is an analyst with an average return of -3.9% and a 37.35% success rate. Blum covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Crispr Therapeutics AG, and Nurix Therapeutics.